Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains
- 1 December 2016
- Vol. 34 (51) , 6610-6616
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 studyThe Lancet Infectious Diseases, 2013
- A Reassortment-Incompetent Live Attenuated Influenza Virus Vaccine for Protection against Pandemic Virus StrainsJournal of Virology, 2011
- Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapyVirology, 2011
- Caution about Newcastle Disease Virus-Based Live Attenuated VaccineJournal of Virology, 2008
- Virus Attenuation by Genome-Scale Changes in Codon Pair BiasScience, 2008
- Substitution of Wild‐Type Yellow Fever Asibi Sequences for 17D Vaccine Sequencesin ChimeriVax–Dengue 4 Does Not Enhance Infection ofAedes aegyptiMosquitoesThe Journal of Infectious Diseases, 2008
- Multiple recombinant dengue type 1 viruses in an isolate from a dengue patientJournal of General Virology, 2007
- Evidence of Intragenic Recombination in G1 Rotavirus VP7 GenesJournal of Virology, 2007
- Current Status of Veterinary VaccinesClinical Microbiology Reviews, 2007
- Reduction of the Rate of Poliovirus Protein Synthesis through Large-Scale Codon Deoptimization Causes Attenuation of Viral Virulence by Lowering Specific InfectivityJournal of Virology, 2006